Phase II Study: Treatment of Non-Hodgkin's Lymphoma With an Oral Antitumor Derivative of Bis(2,6-dioxopiperazine)-Reference-Cited by-同舟云学术

Phase II Study: Treatment of Non-Hodgkin's Lymphoma With an Oral Antitumor Derivative of Bis(2,6-dioxopiperazine)

Published:1992-03-18 Issue:6 Volume:84 Page:435-438
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Ohno Ryuzo,Yamada Kazumasa,Hirano Masami,Shirakawa Shigeru,Tanaka Masao,Oguri Takashi,Kodera Yoshihisa,Mitomo Yasuharu,Ikeda Yasushi,Yokomaku Shozo,Kamiya Osamu,Kobayashi Masahide,Saito Hidehiko,Kimura Kiyoji

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/84/6/435/18078933/84-6-435.pdf

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity;Cancer Chemotherapy and Pharmacology;2007-06-27

2. Durable Remission by Sobuzoxane in an HIV-Seronegative Patient with Human Herpesvirus 8-Negative Primary Effusion Lymphoma;International Journal of Hematology;2004-04-01

3. Development of new topoisomerase II-targeting compounds as candidate anticancer drugs;DNA Topoisomerases in Cancer Therapy;2003

4. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells;Experimental Hematology;2002-11

5. Long-Term Administration of Oral Low-Dose Topoisomerase II Inhibitors, MST-16 and VP-16, for Refractory or Relapsed Non-Hodgkin’s Lymphoma;Acta Haematologica;2000